MEDP - Witness A Substantial Acquisition As Cornelius P. McCarthy III Acquires In Medpace Hldgs Stock Options | Benzinga
Disclosed in a recent SEC filing, Cornelius P. McCarthy III, Director at Medpace Hldgs (NASDAQ:MEDP), made a strategic move by acquiring company stock options on May 21,.
What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday, III, Director at Medpace Hldgs, acquired 953 stock options for MEDP with an exercise price of $393.3 per share.
The Wednesday morning update indicates Medpace Hldgs shares down by 0.0%, currently priced at $396.65. At this value, III's 953 shares are worth $3,192.
Get to Know Medpace Hldgs Better
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Hldgs: Financial Performance Dissected
Revenue Growth: Medpace Hldgs displayed positive ...